Cellular therapy to control tumor progression

Current Opinion in Hematology

Volumn 16, Issue 6, 2009, Pages 437-443

  Kapp, Markus ^a   Rasche, Leo ^a   Einsele, Hermann ^a   Grigoleit, Götz Ulrich ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adoptive immunotherapy; Antitumor immunity; Cytotoxic T lymphocyte

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL THERAPY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 73949096501     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32832f57d4     Document Type: Review

References (41)

1. Ehrlich P. On immunity with special reference to cell life: Croonian lecture. In: Himmelweir B, editor. The collected papers of Paul Ehrlich, vol.II: immunology and cancer research. London, England: Pergamon; 1956. pp. 148-192.
2. Southam CM, Brunschwig A, Levin AG, Dizon QS. Effect of leukocytes on transplantability of human cancer. Cancer 1966; 19:1743-1753.
3. Jamieson BD, Ahmed R. T cell memory. Long-term persistence of virusspecific cytotoxic T cells. J Exp Med 1989; 169:1993-2005. (Pubitemid 19162961)
4. Michle CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360:264-265.
5. KoIb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-2050.
6. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte Infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712-2716.
7. Lokhorst HM, Sohattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18:3031-3037.
8. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Onool 2008; 26:5233-5239.
9. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4' T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
10. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006; 6:409-414.
11. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992;257:238-241.
12. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoprolif erative disorders after bone marrow transplantation: a multiinstitutional study. Blood 1999; 94:2208-2216. (Pubitemid 29467666)
13. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following hematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48:256-269. (Pubitemid 46994875)
14. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108:2874-2880.
15. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
16. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lymphoprollferative disease: results of a phase 2 multicentre clinical trial. Blood 2007; 110:1123-1131. (Pubitemid 47281407)
17. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopolesis-restricted minor histocompatibility antigens HA-1 or HA-2-speoific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003; 100:2742-2747.
18. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285. (Pubitemid 26033083)
19. + T-cell responses to tumorassociated antigens correlate with superior relapse-free survival after alio- SCT. Bone Marrow Transplant 2009; 43:399-410.
20. Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 2007; 110:1924-1932.
21. + T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009; 206:849-866.
22. Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overex- pressing breast cancer. Cancer Immunol immunother 2008; 57:271-280.
23. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62:1462-1470. (Pubitemid 34407808)
24. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213. (Pubitemid 36077915)
25. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumor vessels. Nature 2004; 427:695.
26. Peres E, Wood GW, Poulik J, et al. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 2008; 39:151-156.
27. Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8' T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 31:5060-5069.
28. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-240.
29. - T cell immunity against a tumor/self-antigen is augmented by CD4 ' T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-2601.
30. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306. (Pubitemid 40516155)
31. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-641.
32. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8 ' T cells in lymphopenic hosts. Immunity 1999; 11: 183-190.
33. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-854.
34. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73.
35. Polak L, Geleiok H, Turk JL. Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB. Immunology 1975; 28:939-942.
36. Berd D, Maguire HC Jr, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44:5439-5443. (Pubitemid 15204525)
37. Matar P, Rozados VR, Gonzalez AD, et al. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 2000; 36:1060-1066.
38. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155:1063-1074.
39. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162:6811-6818.
40. Byrd-Leifer CA, Block EF, Takeda K, et al. The role of MyDBS and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001; 31:2448-2457.
41. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294-305.